Services
Investments & Private Equity
Overview
The Investment Advisory and Private Equity activity started in 2004 and generated over USD 1.8 B worth of transactions. Private Equity funds launched initially covered consumer goods and related sectors, and the infrastructure and energy-intensive industries. The activity evolved to encompass club deals, proprietary investments with entry into the digital and biotech economies.
Our Activities
With an investment team operating across MENA and beyond, Swicorp is monitoring its investment portfolio, identifying new opportunities, as well as strategic partners, with a focus on digital, fintech, biotech, e-commerce and other new economy businesses. For larger transactions, Swicorp selectively invests from its own balance sheet and raises co-investor commitments. Two large club deal investments were closed since 2014 with USD 130 million deployed.
In 2016, Swicorp launched an initiative targeting renewable energy and infrastructure assets in the MEA region in partnership with Acciona, a leading global renewable energy project developer and manager. Swicorp's objective is to build on its successful first project in Egypt (3 x 50 MW PV in Egypt) and lead the development of a platform targeting USD 2 billion worth of projects under management.
In 2016, Swicorp's historic private equity team was spun off into SPE Capital. In 2019, SPE Capital launched its AIF Fund targeting investments in mid-size companies in Africa and AUM in excess of USD 200 million. For more information, visit www.spe-capital.com.
Portfolio

Manufacturer and marketer of long steel and fencing material in Saudi Arabia with presence in Jeddah, Riyadh and Dammam

Provider of manpower services, including cleaning, maids, pest control, gardening, sanitization, facilities management in Saudi Arabia with presence in Jeddah, Riyadh and Dammam

Shariah-compliant mortgage loan provider in Saudi Arabia

Disruptive logistics firm in the last-mile delivery space

3 x 50 MW Solar Photovoltaic Project in Egypt (USD 180 M). Commercial operations started February 2019.

MoC 1.7x
IRR 11.6%

Medical research and development for tissue-level regeneration. Development of therapeutics to address a range of degenerative diseases, regenerative medicine and oncology

E-commerce for maternity and child products

VC Co-investment alongside world-class lead investors in Endeavor companies